Compare NSA & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSA | STOK |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2015 | 2019 |
| Metric | NSA | STOK |
|---|---|---|
| Price | $27.76 | $32.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $33.22 | $33.11 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.61 | ★ 0.68 |
| Revenue | ★ $741,511,000.00 | $205,632,000.00 |
| Revenue This Year | N/A | $430.24 |
| Revenue Next Year | $1.27 | N/A |
| P/E Ratio | ★ $45.24 | $46.53 |
| Revenue Growth | N/A | ★ 1128.17 |
| 52 Week Low | $27.49 | $5.35 |
| 52 Week High | $40.62 | $38.69 |
| Indicator | NSA | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 34.02 | 53.64 |
| Support Level | $29.01 | $31.50 |
| Resistance Level | $30.10 | $33.90 |
| Average True Range (ATR) | 0.56 | 2.25 |
| MACD | -0.16 | -0.15 |
| Stochastic Oscillator | 10.78 | 38.02 |
National Storage Affiliates Trust Trust is a real estate investment trust. The company owns, operates, and acquires self-storage properties located within the metropolitan statistical areas throughout the United States. With the help of property management platform, the company manages and controls the day-to-day operations and affairs of consolidated properties and unconsolidated real estate ventures under the iStorage, SecurCare, RightSpace, Northwest and Move It brands.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.